A new class of drug may increase alertness without any of the jitteriness of over-stimulation, suggest the results of a small clinical trial released this week.

A compound dubbed CX717, a member of the new class called ampakines, significantly improved performance on tests of memory, attention, alertness, reaction time and problem solving in healthy men deprived of sleep.

The study was carried out by Julia Boyle at the Sleep Research Centre at the University of Surrey, UK, and her colleagues on behalf of Cortex Pharmaceuticals Inc., based in Irvine, California, US.

Link to dissertation